Dr Nikolaos Diamantis, Consultant Medical Oncologist, Gastrointestinal Cancers & Neuroendocrine Tumours
Dr Nikolaos Diamantis
Consultant Medical Oncologist, Gastrointestinal Cancers & Neuroendocrine Tumours
Dr Nikolaos Diamantis MD MRCP PhD
Consultant Medical Oncologist, Gastrointestinal Cancers & Neuroendocrine Tumours
Dr Nikolaos Diamantis
Consultant Medical Oncologist, Gastrointestinal Cancers & Neuroendocrine Tumours MD MRCP PhD
Dr Diamantis is a Consultant Medical Oncologist, Gastrointestinal Cancers & Neuroendocrine Tumours
Areas of expertise
- Bile duct cancer (cholangiocarcinoma)
- Bowel cancer
- Colorectal cancer
- Gastrointestinal cancers
- Medical oncology
Make an appointment
Address
-
LOC at Platinum Medical Centre
15-17 Lodge Road, St Johns Wood, London, NW8 7JA
-
LOC - Leaders in Oncology Care
95-97 Harley Street, London, W1G 6AF
About Dr Nikolaos Diamantis
GMC number: 7013255
Year qualified: 2004
Place of primary qualification: National Capodistrian University of Athens
Areas of expertise
- Adenocarcinoma
- Barrett's oesophagus
- Bile duct cancer (cholangiocarcinoma)
- Biliary cancer
- Bowel cancer
- Cancer of unknown primary
- Cancer prevention and screening
- Carcinoma of unknown primary
- Chemotherapy
- Clinical trials
- Colon cancer
- Colorectal cancer
- Gallbladder cancer
- Gastrointestinal cancers
- Gastro-intestinal malignancies
- Immunotherapy
- Liver cancer
- Medical oncology
- Neoadjuvant
- Neuroendocrine tumours
- Oesophageal cancer
- Oligometastic disease
- Pancreatic cancer
- Rare cancer
- Rectal cancer
- Small bowel cancer
- Stomach (gastric) cancer
- Targeted therapy
Professional memberships
Articles by Dr Nikolaos Diamantis
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer
Time-dependent covid-19 mortality in patients with cancer
Covid-19 sequelae and the host proinflammatory response
Persistence of long-term COVID-19 sequelae in patients with cancer
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection
COVID-19 in breast cancer patients
